BioSpace News Archive

CareDx, Inc. announced that it has delivered over 200,000 AlloMap® or AlloSure® results for over 30,000 heart transplant recipients.

Applied Genetic Technologies Corporation today announced that Sue Washer, President & Chief Executive Officer, will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean in Barcelona, Spain on Thursday, April 21 at 9:30 PM CEST / 3:30 PM ET.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its first data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH).

Amyris, Inc. successfully hosted an in-person investor event following the Company’s Nasdaq Opening Bell Ringing Ceremony.

Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114.

Rheos Medicines today announced the appointment of Katerina Leftheris, Ph.D., as Senior Vice President of Drug Discovery, and Nabil Uddin, Pharm.D., as Vice President of Strategy.

Rheos Medicines today announced that it has appointed Soumya Raychaudhuri, M.D., Ph.D., and Cornelia Weyand, M.D., to its Scientific Advisory Board (SAB).

Second Sight Medical Products, Inc. today announced that an interview with Adam Mendelsohn, Ph.D. will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET).

Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.  

Celsion Corporation and Medidata today announced that they presented their findings on the use of a Synthetic Control Arm Ⓡ (SCA) in a completed Phase Ib dose-escalating study of GEN-1 in the neoadjuvant treatment of patients with Stage III/IV ovarian cancer.